Joshua Bleharski
Director · Scribe Therapeutics, Inc.
Individual
- 2026
- Jul 28, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Joshua Bleharski files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Behzad Aghazadeh - $36.26M in SCTX purchases and sales in the last 12 months
- ORBIMED ADVISORS LLC - $15.00M in SCTX purchases and sales in the last 12 months
- Carl L. Gordon - $15.00M in SCTX purchases and sales in the last 12 months
- AH Bio Fund II, L.P. - $5.00M in SCTX purchases and sales in the last 12 months
- Svetlana Lucas - $45K in SCTX purchases and sales in the last 12 months
- David Parrot - $40K in SCTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Joshua Bleharski?
Joshua Bleharski is a corporate insider, tracked as Director of Scribe Therapeutics, Inc. (SCTX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Joshua Bleharski submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.